Hims & Hers Stock Takes a Hit as FDA Resolves Drug Shortages

Category: Finance

Hims & Hers stock has plummeted following the FDA's announcement that shortages of key weight-loss drugs have ended. The news has raised concerns about reduced demand for the company's products, leading to significant stock declines.

Shares of Hims & Hers Health have experienced a significant drop in value following the U.S. Food and Drug Administration's announcement that the shortages of popular weight-loss drugs, including Novo Nordisk's Ozempic and Wegovy, have been resolved. The FDA's declaration has led to a 26% decrease in Hims & Hers stock, as the resolution of these shortages is expected to reduce demand for the company's offerings that are based on the same active ingredients. Various news outlets reported that the stock fell by as much as 25% in response to the FDA's update, marking a challenging time for the telehealth company. Analysts suggest that this situation could impact the market for compounded GLP-1 medications, which have gained popularity during the shortage. The FDA's decision is seen as a win for Novo Nordisk but poses challenges for Hims & Hers and similar companies reliant on these medications.

Reference

Updated At: 2/22/2025

Related Articles

Shares of Hims & Hers tumble 26% after FDA says semaglutide is no longer in shortage

Shares of Hims & Hers Health fell 26% after the FDA announced the resolution of the semaglutide injection shortage. Semaglutide is the key ingredient in popular weight loss and diabetes drugs, leading to increased demand for compounded alternatives from digital health companies like Hims & Hers. Compounded drugs are custom-made and typically cheaper than brand-name options, with Hims & Hers offering semaglutide for under $200 per month compared to around $1,000 for branded versions.

CNBC

Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply

Shares of Hims & Hers Health dropped over 23% after the FDA announced the resolution of a shortage of semaglutide, impacting the company's compounded weight-loss drug offerings. CEO Andrew Dudum stated the company will monitor future shortages while continuing to provide personalized treatments legally.

Investopedia

Hims & Hers Stock Falls 19% Following FDA Update on Ozempic and Wegovy

Hims & Hers Health shares fell 20.4% after the FDA announced the end of shortages for Novo Nordisk's weight loss drugs, impacting Hims & Hers' compounded semaglutide sales. The company is focused on expanding its infrastructure and has purchased a peptide plant in California to enhance its domestic supply chain for customized drugs, aiming for better control over product availability and quality.

Yahoo Eurosport UK